This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with great interest the article by Enk and Knop¹ and the accompanying editorial by Stanley.² We were very impressed with the dramatic and rapid improvement obtained in 12 patients with pemphigus vulgaris with the use of mycophenolate mofetil, 2 g/d, as a steroid-sparing immunosuppressive agent. However, based on our own experience treating patients with autoimmune and inflammatory skin diseases, we feel that there are 3 aspects of this article that deserve further discussion and comment.

First, we have found that a 2-g/d dosage of mycophenolate is quite effective in treating patients with inflammatory skin diseases such as pyoderma gangrenosum, Crohn disease, psoriasis, chronic actinic dermatitis, lichen planus, and bullous pemphigoid.^3-4 In these disorders, T lymphocytes and polymorphonuclear cells play a crucial role in tissue injury. However, for diseases such as pemphigus, when the therapeutic goal is inhibition of autoantibody synthesis by B cells,⁵ we found that higher doses . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus With Mycophenolate Mofetil
Mimouni et al.
Arch Dermatol 2003;139:739-742.
ABSTRACT | FULL TEXT